Digestive System Diseases

All Conditions

Symptoms and General Pathology

Gastric Outlet Obstruction

Pyloric Stenosis

Constriction, Pathologic

Stomach Diseases

Gastrointestinal Diseases

An anastomosis will be created between the stomach and the proximal loop of the jejunum during a laparoscopic surgical procedure.

A stent is placed between the stomach and adjacent small intestine under endoscopic ultrasound guidance during an upper endoscopic procedure.

Surgical gastrojejunostomy (SGJ)

Endoscopic ultrasound (EUS) guided gastrojejunostomy

Endoscopic gastrojejunostomy (EGJ)

Molly Stewart

Hye Jeong Jang

Matthew Weiss, MD

Sandeep Anantha, MD

John Wang, MD

Arvind Trindade, MD

Petros Benias, MD

Gastric outlet obstruction (GOO) occurs commonly in malignancies involving the periampullary region (cancers originating in the head of the pancreas, duodenum, bile duct, or ampulla) or the distal stomach. GOO not only causes debilitating symptoms such as nausea, vomiting, inability to tolerate oral intake, and prevents adequate nutritional intake. Therefore, providing therapy for GOO is imperative to improve the quality of life, and nutritional status of these patients, as well as allow them to continue receiving their cancer treatment

After potential subjects are screened from the physicians' schedules, they will be assessed for further inclusion criteria. They will be presented with the informed consent form for their review. Once they have been given the opportunity to review and ask questions, they will sign the consent form and from this point will be considered enrolled into the study.

After signing the informed consent, subjects will be randomized to one of the two cohorts in a 1:1 manner.

On the day of their assigned procedures, subjects will be asked several quality of life questionnaires to obtain a baseline status.

Data will be collected during and immediately following the procedure to assess for any possible adverse events.

Follow-up data will be completed at the following timepoints: 1-day, 2-day, 3-day, 4-day, and 7-day, 30-day, 3-month, 6-month, and 1-year post-procedure.

QOL Scoring Systems GOOSS- Gastric Outlet Obstruction Symptom Score

* 1 Inadequate or no oral intake
* 2 Liquids/thickened liquids
* 3 Semisolids/ low residue
* 4 unmodified

GFS- Gut Function Score from Lowe et al 2002

* 0 Profuse vomiting
* 1 Nausea and occasional vomiting
* 2 Nausea only
* 3 Normal gut function

Pre-Procedure Variables to Record Demographic

* Gender
* Weight
* BMI
* Cancer Type

Clinical Parameters

* GOOSS
* Gut Function Score
* Karnofsky Performance Scale

Procedural Parameters

* EUS-GJ: presence of ascites, able to pass scope beyond obstruction, use of wire to stabilize position, Length of procedure, intraprocedural AEs, Stent size used, successful completion of procedure
* Laparoscopic GJ: presence of ascites, length of procedure, intraprocedural AEs, conversion to open GJ, successful completion of procedure

Post-procedure Hospitalization Daily Function

* GOOSS
* Gut Function Score
* Time to initiation of oral intake liquids
* Time to initiation of oral intake solids
* Time to discharge
* Post procedural AEs

  30 Day Outcomes
* GOOSS
* Gut Function Score
* Karnofsky Performance Scale
* Weight/BMI
* Able to tolerate TB approved chemotherapeutic regimen

Subjects will be randomly assigned in a 1:1 ratio to surgical gastrojejunostomy (SGJ) or endoscopic gastrojejunostomy (EGJ).

Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy

Days to initiation of solid oral intake will be measured from randomization to first day of intake of soft solid foods, as indicated by a GOOSS score of 2

All adverse events (AEs) occurring after treatment will be graded according to ASGE lexicon. A subject will be considered to have had an adverse event if they had one or more adverse events, and they will be considered to have had a serious adverse event (SAE) if they had one or more serious adverse events

Technical success is defined as adequate deployment and positioning of the stent(s) for EGJ or technical possibility to create an anastomosis for SGJ.

Clinical success is defined as improvement to a GOOSS score of 2 or 3 (oral intake of soft solid foods or resumption of full diet) without additional intervention.

Length of stay will be measured from randomization to discharge alive. All patients will be followed until discharge. Patients who die in hospital will be considered censored and time from randomization to death will be used.

BMI will be measured immediately prior to the procedure, and at one month and three months after the procedure.

Albumin levels will be measured immediately prior to the procedure, and at one month and three months after the procedure.

The Gastric Outlet Obstruction Symptom Score (GOOSS) scale is as follows, whereas a score of 1 is the worst and a score of 4 is the best:

1. Inadequate or no oral intake
2. Liquids/thickened liquids
3. Semisolids/ low residue
4. Unmodified

GOOSS will be recorded at each of the following timepoints:

* immediately prior to the procedure
* immediately post-procedure
* 1-day post-procedure
* 2-days post-procedure
* 3-days post-procedure
* 4-days post-procedure
* 7-days post-procedure,
* 30-days post-procedure
* 3-months post-procedure
* 6-months post-procedure
* 1-year post-procedure

Gut Function Score (GFS) scale is as follows, whereas a score of 1 is the worst and a score of 3 is the best:

0. Profuse vomiting

1. Nausea and occasional vomiting
2. Nausea only
3. Normal gut function

GFS will be recorded at each of the following timepoints:

* Immediately prior to the procedure
* Immediately post-procedure
* 1-day post-procedure
* 2-days post-procedure
* 3-days post-procedure
* 4-days post-procedure
* 7-days post-procedure,
* 30-days post-procedure
* 3-months post-procedure
* 6-months post-procedure
* 1-year post-procedure

Karnofsky Performance Scale is measured on a scale of 0 to 100 as follows, with a score of 0 being the worst and a score of 100 being the best:

100 - Normal; no complaints; no evidence of disease. 90 - Able to carry on normal activity; minor signs or symptoms of disease. 80 - Normal activity with effort; some signs or symptoms of disease. 70 - Cares for self; unable to carry on normal activity or to do active work. 60 - Requires occasional assistance, but is able to care for most of their personal needs.

50 - Requires considerable assistance and frequent medical care. 40 - Disabled; requires special care and assistance. 30 - Severely disabled; hospital admission is indicated although death not imminent.

20 - Very sick; hospital admission necessary; active supportive treatment necessary.

10 - Moribund; fatal processes progressing rapidly. 0 - Dead

KPS will be recorded pre-procedure and at 30-days post-procedure.

Ability to tolerate TB approved chemotherapeutic regimen

Spots Global Cancer Trial Database for periampullary malignancy